Using two different lymphatic specific cre-promoters (Prox-1 and Flt4, respectively) to induce MHC-II deletion in LECs, Gkoutidi et al. and our laboratory arrived at the complementary finding that deletion of MHC-II expression in LECs results in impaired primary tumor growth [26]. The gene discussed is FLT4; the disease is neoplasm.